Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

@article{Liang2015EnhancedNA,
  title={Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.},
  author={Bo Liang and Sonja R. Surman and Em{\'e}rito Amaro-Carambot and Barbora Kabatova and Natalie A Mackow and Matthias Lingemann and Lijuan Yang and Jason S McLellan and Barney S. Graham and Peter D. Kwong and Anne Schaap-Nutt and Peter L. Collins and Shirin Munir},
  journal={Journal of virology},
  year={2015},
  volume={89 18},
  pages={9499-510}
}
UNLABELLED Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and second leading viral agents of severe respiratory tract disease in infants and young children worldwide. Vaccines are not available, and an RSV vaccine is particularly needed. A live attenuated chimeric recombinant bovine/human PIV3 (rB/HPIV3) vector expressing the RSV fusion (F) glycoprotein from an added gene has been under development as a bivalent vaccine against RSV and HPIV3… CONTINUE READING